SAFE-HEaRt: A Pilot Study Assessing the Cardiac SAFEty of HER2 Targeted Therapy in Patients With HER2 Positive Breast Cancer and Reduced Left Ventricular Function
Phase of Trial: Phase II
Latest Information Update: 25 Jan 2016
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Trastuzumab emtansine (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- Acronyms SAFE-HEaRt
- 07 Jun 2017 Biomarkers information updated
- 08 Feb 2015 Planned number of patients changed from 33 to 30, as reported by ClinicalTrials.gov.
- 20 Aug 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.